APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peptide-Radionuclide Conjugates (PRCs)

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Peptide-Radionuclide Conjugates (PRCs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025180 pages

Choose your research edition.

Industry ResearchPeptide-Radionuclide Conjugates (PRCs) Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide-Radionuclide Conjugates (PRCs) Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Peptide-Radionuclide Conjugates (PRCs) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide-Radionuclide Conjugates (PRCs) Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide-Radionuclide Conjugates (PRCs) Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Peptide-Radionuclide Conjugates (PRCs) market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Peptide-Radionuclide Conjugates (PRCs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Peptide-Radionuclide Conjugates (PRCs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Peptide-Radionuclide Conjugates (PRCs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Peptide-Radionuclide Conjugates (PRCs) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Peptide-Radionuclide Conjugates (PRCs) include Grand Pharmaceutical, Novartis, Telix Pharmaceutical, RadioMedix, ITM Radiopharma and Curium Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Peptide-Radionuclide Conjugates (PRCs) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Peptide-Radionuclide Conjugates (PRCs) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Peptide-Radionuclide Conjugates (PRCs) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Peptide-Radionuclide Conjugates (PRCs) market size, projected growth trends, production technologies, key applications, and end-use industries.

Peptide-Radionuclide Conjugates (PRCs) Segment by Company

Grand Pharmaceutical

Novartis

Telix Pharmaceutical

RadioMedix

ITM Radiopharma

Curium Pharma

Peptide-Radionuclide Conjugates (PRCs) Segment by Type

Diagnostic PRCs

Therapeutic PRCs

Peptide-Radionuclide Conjugates (PRCs) Segment by Application

Prostate Cancer

Neuroendocrine Tumors

Other

Peptide-Radionuclide Conjugates (PRCs) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide-Radionuclide Conjugates (PRCs) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide-Radionuclide Conjugates (PRCs) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide-Radionuclide Conjugates (PRCs).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Peptide-Radionuclide Conjugates (PRCs) market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Peptide-Radionuclide Conjugates (PRCs) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Peptide-Radionuclide Conjugates (PRCs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Peptide-Radionuclide Conjugates (PRCs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Peptide-Radionuclide Conjugates (PRCs) Industry Trends Table 2. Peptide-Radionuclide Conjugates (PRCs) Industry Drivers Table 3. Peptide-Radionuclide Conjugates (PRCs) Industry Opportunities and Challenges Table 4. Peptide-Radionuclide Conjugates (PRCs) Industry Restraints Table 5. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Manufacturers Table 9. Global Peptide-Radionuclide Conjugates (PRCs) Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Peptide-Radionuclide Conjugates (PRCs) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Peptide-Radionuclide Conjugates (PRCs) Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Peptide-Radionuclide Conjugates (PRCs) Manufacturers, Product Type & Application Table 13. Global Peptide-Radionuclide Conjugates (PRCs) Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Peptide-Radionuclide Conjugates (PRCs) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Diagnostic PRCs Table 17. Major Manufacturers of Therapeutic PRCs Table 18. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2026) & (K Units) Table 20. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2027-2032) & (K Units) Table 21. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Type (2021-2026) Table 22. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Type (2027-2032) Table 23. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2021-2026) & (K Units) Table 25. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2027-2032) & (K Units) Table 26. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Type (2021-2026) Table 27. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Prostate Cancer Table 29. Major Manufacturers of Neuroendocrine Tumors Table 30. Major Manufacturers of Other Table 31. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021-2026) & (K Units) Table 33. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2027-2032) & (K Units) Table 34. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Application (2021-2026) Table 35. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Application (2027-2032) Table 36. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2021-2026) & (K Units) Table 38. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2027-2032) & (K Units) Table 39. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Application (2021-2026) Table 40. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Application (2027-2032) Table 41. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Region (2021-2026) & (K Units) Table 43. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Region (2021-2026) Table 44. Global Peptide-Radionuclide Conjugates (PRCs) Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Peptide-Radionuclide Conjugates (PRCs) Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Peptide-Radionuclide Conjugates (PRCs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021-2026) & (K Units) Table 48. North America Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2027-2032) & (K Units) Table 49. Europe Peptide-Radionuclide Conjugates (PRCs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021-2026) & (K Units) Table 51. Europe Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Peptide-Radionuclide Conjugates (PRCs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Peptide-Radionuclide Conjugates (PRCs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2027-2032) & (K Units) Table 58. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Region (2021-2026) Table 62. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Region (2027-2032) Table 63. Grand Pharmaceutical Company Information Table 64. Grand Pharmaceutical Business Overview Table 65. Grand Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Grand Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Product Portfolio Table 67. Grand Pharmaceutical Recent Development Table 68. Novartis Company Information Table 69. Novartis Business Overview Table 70. Novartis Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Novartis Peptide-Radionuclide Conjugates (PRCs) Product Portfolio Table 72. Novartis Recent Development Table 73. Telix Pharmaceutical Company Information Table 74. Telix Pharmaceutical Business Overview Table 75. Telix Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Telix Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Product Portfolio Table 77. Telix Pharmaceutical Recent Development Table 78. RadioMedix Company Information Table 79. RadioMedix Business Overview Table 80. RadioMedix Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. RadioMedix Peptide-Radionuclide Conjugates (PRCs) Product Portfolio Table 82. RadioMedix Recent Development Table 83. ITM Radiopharma Company Information Table 84. ITM Radiopharma Business Overview Table 85. ITM Radiopharma Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. ITM Radiopharma Peptide-Radionuclide Conjugates (PRCs) Product Portfolio Table 87. ITM Radiopharma Recent Development Table 88. Curium Pharma Company Information Table 89. Curium Pharma Business Overview Table 90. Curium Pharma Peptide-Radionuclide Conjugates (PRCs) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Curium Pharma Peptide-Radionuclide Conjugates (PRCs) Product Portfolio Table 92. Curium Pharma Recent Development Table 93. Key Raw Materials Table 94. Raw Materials Key Suppliers Table 95. Peptide-Radionuclide Conjugates (PRCs) Distributors List Table 96. Peptide-Radionuclide Conjugates (PRCs) Customers List Table 97. Research Programs/Design for This Report Table 98. Authors List of This Report Table 99. Secondary Sources Table 100. Primary Sources List of Figures Figure 1. Peptide-Radionuclide Conjugates (PRCs) Product Image Figure 2. Global Peptide-Radionuclide Conjugates (PRCs) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide-Radionuclide Conjugates (PRCs) Market Size (2021-2032) & (US$ Million) Figure 4. Global Peptide-Radionuclide Conjugates (PRCs) Sales (2021-2032) & (K Units) Figure 5. Global Peptide-Radionuclide Conjugates (PRCs) Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Peptide-Radionuclide Conjugates (PRCs) Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Diagnostic PRCs Image Figure 9. Therapeutic PRCs Image Figure 10. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Type (2021-2032) Figure 13. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Type (2021-2032) Figure 16. Prostate Cancer Image Figure 17. Neuroendocrine Tumors Image Figure 18. Other Image Figure 19. Global Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Application (2021-2032) Figure 22. Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Application (2021-2032) Figure 25. North America Peptide-Radionuclide Conjugates (PRCs) Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Country (2021-2032) Figure 27. U.S. Peptide-Radionuclide Conjugates (PRCs) Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Peptide-Radionuclide Conjugates (PRCs) Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Peptide-Radionuclide Conjugates (PRCs) Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Peptide-Radionuclide Conjugates (PRCs) Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Country (2021-2032) Figure 32. Germany Peptide-Radionuclide Conjugates (PRCs) Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Peptide-Radionuclide Conjugates (PRCs) Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Peptide-Radionuclide Conjugates (PRCs) Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Peptide-Radionuclide Conjugates (PRCs) Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Peptide-Radionuclide Conjugates (PRCs) Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Peptide-Radionuclide Conjugates (PRCs) Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Country (2021-2032) Figure 39. China Peptide-Radionuclide Conjugates (PRCs) Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Peptide-Radionuclide Conjugates (PRCs) Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Peptide-Radionuclide Conjugates (PRCs) Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Peptide-Radionuclide Conjugates (PRCs) Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Peptide-Radionuclide Conjugates (PRCs) Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Peptide-Radionuclide Conjugates (PRCs) Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Peptide-Radionuclide Conjugates (PRCs) Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Country (2021-2032) Figure 47. Brazil Peptide-Radionuclide Conjugates (PRCs) Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Peptide-Radionuclide Conjugates (PRCs) Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Peptide-Radionuclide Conjugates (PRCs) Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Peptide-Radionuclide Conjugates (PRCs) Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Peptide-Radionuclide Conjugates (PRCs) Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Peptide-Radionuclide Conjugates (PRCs) Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Peptide-Radionuclide Conjugates (PRCs) Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Peptide-Radionuclide Conjugates (PRCs) Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Peptide-Radionuclide Conjugates (PRCs) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Figure 58. North America Peptide-Radionuclide Conjugates (PRCs) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Figure 60. Europe Peptide-Radionuclide Conjugates (PRCs) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Peptide-Radionuclide Conjugates (PRCs) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Peptide-Radionuclide Conjugates (PRCs) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Peptide-Radionuclide Conjugates (PRCs) Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Peptide-Radionuclide Conjugates (PRCs) Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Diagnostic PRCs
  • Therapeutic PRCs
Applications
  • Prostate Cancer
  • Neuroendocrine Tumors
  • Other
Companies covered
  • Grand Pharmaceutical
  • Novartis
  • Telix Pharmaceutical
  • RadioMedix
  • ITM Radiopharma
  • Curium Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Peptide-Radionuclide Conjugates (PRCs) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Peptide-Radionuclide Conjugates (PRCs) Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Peptide-Radionuclide Conjugates (PRCs) Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Peptide-Radionuclide Conjugates (PRCs) Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Peptide-Radionuclide Conjugates (PRCs) Market Dynamics
  1. 2.1 Peptide-Radionuclide Conjugates (PRCs) Industry Trends
  2. 2.2 Peptide-Radionuclide Conjugates (PRCs) Industry Drivers
  3. 2.3 Peptide-Radionuclide Conjugates (PRCs) Industry Opportunities and Challenges
  4. 2.4 Peptide-Radionuclide Conjugates (PRCs) Industry Restraints
3 Peptide-Radionuclide Conjugates (PRCs) Market by Manufacturers
  1. 3.1 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Manufacturers (2021-2026)
  3. 3.3 Global Peptide-Radionuclide Conjugates (PRCs) Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Peptide-Radionuclide Conjugates (PRCs) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Peptide-Radionuclide Conjugates (PRCs) Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Peptide-Radionuclide Conjugates (PRCs) Manufacturers, Product Type & Application
  7. 3.7 Global Peptide-Radionuclide Conjugates (PRCs) Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Peptide-Radionuclide Conjugates (PRCs) Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Peptide-Radionuclide Conjugates (PRCs) Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Peptide-Radionuclide Conjugates (PRCs) Tier 1, Tier 2, and Tier 3
4 Peptide-Radionuclide Conjugates (PRCs) Market by Type
  1. 4.1 Peptide-Radionuclide Conjugates (PRCs) Type Introduction
  2. 4.1.1 Diagnostic PRCs
  3. 4.1.2 Therapeutic PRCs
  4. 4.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Type
  5. 4.2.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Type (2021-2032)
  7. 4.2.3 Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Type (2021-2032)
  8. 4.3 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Type
  9. 4.3.1 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Type (2021-2032)
  11. 4.3.3 Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Type (2021-2032)
5 Peptide-Radionuclide Conjugates (PRCs) Market by Application
  1. 5.1 Peptide-Radionuclide Conjugates (PRCs) Application Introduction
  2. 5.1.1 Prostate Cancer
  3. 5.1.2 Neuroendocrine Tumors
  4. 5.1.3 Other
  5. 5.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Application
  6. 5.2.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Application (2021-2032)
  8. 5.2.3 Global Peptide-Radionuclide Conjugates (PRCs) Sales Market Share by Application (2021-2032)
  9. 5.3 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Application
  10. 5.3.1 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Application (2021-2032)
  12. 5.3.3 Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Application (2021-2032)
6 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Region
  1. 6.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Region (2021-2032)
  3. 6.2.1 Global Peptide-Radionuclide Conjugates (PRCs) Sales by Region (2021-2026)
  4. 6.2.2 Global Peptide-Radionuclide Conjugates (PRCs) Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Peptide-Radionuclide Conjugates (PRCs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Peptide-Radionuclide Conjugates (PRCs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Peptide-Radionuclide Conjugates (PRCs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Peptide-Radionuclide Conjugates (PRCs) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Peptide-Radionuclide Conjugates (PRCs) Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Region
  1. 7.1 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Region
  2. 7.1.1 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Region (2021-2026)
  4. 7.1.3 Global Peptide-Radionuclide Conjugates (PRCs) Revenue by Region (2027-2032)
  5. 7.1.4 Global Peptide-Radionuclide Conjugates (PRCs) Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032)
  8. 7.2.2 North America Peptide-Radionuclide Conjugates (PRCs) Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032)
  11. 7.3.2 Europe Peptide-Radionuclide Conjugates (PRCs) Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Peptide-Radionuclide Conjugates (PRCs) Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Peptide-Radionuclide Conjugates (PRCs) Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Peptide-Radionuclide Conjugates (PRCs) Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Grand Pharmaceutical
  2. 8.1.1 Grand Pharmaceutical Company Information
  3. 8.1.2 Grand Pharmaceutical Business Overview
  4. 8.1.3 Grand Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Grand Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
  6. 8.1.5 Grand Pharmaceutical Recent Developments
  7. 8.2 Novartis
  8. 8.2.1 Novartis Company Information
  9. 8.2.2 Novartis Business Overview
  10. 8.2.3 Novartis Peptide-Radionuclide Conjugates (PRCs) Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Novartis Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
  12. 8.2.5 Novartis Recent Developments
  13. 8.3 Telix Pharmaceutical
  14. 8.3.1 Telix Pharmaceutical Company Information
  15. 8.3.2 Telix Pharmaceutical Business Overview
  16. 8.3.3 Telix Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Telix Pharmaceutical Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
  18. 8.3.5 Telix Pharmaceutical Recent Developments
  19. 8.4 RadioMedix
  20. 8.4.1 RadioMedix Company Information
  21. 8.4.2 RadioMedix Business Overview
  22. 8.4.3 RadioMedix Peptide-Radionuclide Conjugates (PRCs) Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 RadioMedix Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
  24. 8.4.5 RadioMedix Recent Developments
  25. 8.5 ITM Radiopharma
  26. 8.5.1 ITM Radiopharma Company Information
  27. 8.5.2 ITM Radiopharma Business Overview
  28. 8.5.3 ITM Radiopharma Peptide-Radionuclide Conjugates (PRCs) Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 ITM Radiopharma Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
  30. 8.5.5 ITM Radiopharma Recent Developments
  31. 8.6 Curium Pharma
  32. 8.6.1 Curium Pharma Company Information
  33. 8.6.2 Curium Pharma Business Overview
  34. 8.6.3 Curium Pharma Peptide-Radionuclide Conjugates (PRCs) Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Curium Pharma Peptide-Radionuclide Conjugates (PRCs) Product Portfolio
  36. 8.6.5 Curium Pharma Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Peptide-Radionuclide Conjugates (PRCs) Value Chain Analysis
  2. 9.1.1 Peptide-Radionuclide Conjugates (PRCs) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Peptide-Radionuclide Conjugates (PRCs) Production Mode & Process
  6. 9.2 Peptide-Radionuclide Conjugates (PRCs) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Peptide-Radionuclide Conjugates (PRCs) Distributors
  9. 9.2.3 Peptide-Radionuclide Conjugates (PRCs) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst